Skip to main content
S 2253Health Insurance

Insurance - Prescription Drug Benefits

This bill requires insurers to count third-party payments, like coupons, toward a patient's deductible and out-of-pocket maximums.

Introduced36 Yea0 Nay2 Not voting
Population
Affected
35
Introduced Jan 23, 2026Committee Senate Health & Human Services

Plain-English Summary

This legislation changes how health insurance companies and pharmacy benefit managers calculate a patient's out-of-pocket costs for prescription drugs. Specifically, it mandates that any payments made by the patient, or by someone else on their behalf (such as through a drug manufacturer's coupon or a charitable assistance program), must count toward the patient's deductible and out-of-pocket maximum. This rule applies to brand-name drugs without generics or drugs obtained through specific approval processes. It includes exceptions to ensure High Deductible Health Plans remain compliant with federal tax laws regarding Health Savings Accounts (HSAs).

For younger readers

Imagine you have a piggy bank that you must fill up with money before your insurance company starts paying for your medicine. Sometimes, nice people or companies give you coupons to help put money in that piggy bank. Right now, some insurance companies say that "coupon money" doesn't count toward filling the pig. This new law says that the coupon money must count. This helps you fill up the piggy bank faster so the insurance company starts paying for your medicine sooner.

Who & Where It Applies

Impacted groups
Patients with chronic illnessesHealth insurance carriersPharmacy benefit managersPharmaceutical manufacturersEmployers sponsoring health plans
Impacted communities
All

Constitutional & Fiscal Check

None Likely

Estimated cost
None
Estimated revenue
None

Bill Analysis

Both viewpoints
For Progressives
  • Protects vulnerable patients with chronic conditions from high out-of-pocket costs by ensuring that financial assistance actually reduces their deductible burden.
  • Prevents insurance companies from "double-dipping" by collecting the full deductible from a third party while still requiring the patient to pay that amount again to meet their cap.
  • Increases access to necessary medications for low-income individuals who rely on copay assistance programs to afford life-saving prescriptions.
  • May inadvertently support high pharmaceutical prices by allowing drug manufacturers to use coupons to mask the true cost of drugs, rather than lowering prices.
  • The delay in implementation until January 1, 2027, leaves patients vulnerable to these insurance practices for several more years.
  • Does not address the systemic issue of high deductibles and cost-sharing requirements that make healthcare unaffordable in the first place.
For Conservatives
  • Ensures that consumers get the full benefit of the contracts and assistance programs they utilize, protecting them from deceptive accounting by insurers.
  • Includes specific provisions to protect Health Savings Accounts (HSAs), ensuring that tax-advantaged savings vehicles are not jeopardized by state regulations.
  • Supports the pharmaceutical industry's ability to offer competitive pricing assistance without interference from insurance middlemen.
  • Represents government interference in private contracts between insurance companies and their enrollees regarding how costs are calculated.
  • Could lead to higher insurance premiums for everyone if insurers raise rates to compensate for the revenue lost from enforcing deductibles.
  • Distorts free-market price signals by insulating consumers from the actual cost of expensive brand-name drugs.

Votes

Loading votes...

Full Bill Text

Changes to existing Rhode Island law · 42 additions · 3 deletions

SECTION 1. Section 27-20.8-1 of the General Laws in Chapter 27-20.8 entitled "Prescription Drug Benefits" is hereby amended to read as follows: 27-20.8-1. Definitions. For the purposes of this chapter, the following terms shall mean:

(1) “Cost sharing” shall mean any copayment, coinsurance, deductible, or annual limitation on cost sharing including, but not limited to, a limitation subject to 42 U.S.C. §§ 18022(c) and 300gg-6(b), required by or on behalf of an enrollee in order to receive a specific healthcare service, including a prescription drug, covered by a health plan, whether covered under the medical or pharmacy benefit. (1)(2) “Director” shall mean the director of the department of business regulation. (2)(3) “Health plan” shall mean an insurance carrier as defined in chapters 18, 19, 20, and 41 of this title. (3)(4) “Insured” shall mean any person who is entitled to have pharmacy services paid by a health plan pursuant to a policy, certificate, contract, or agreement of insurance or coverage including those administered for the health plan under a contract with a third-party administrator that manages pharmacy benefits or pharmacy network contracts.

(5) “Insurer” shall mean any person, firm, or corporation offering and/or insuring healthcare services on a prepaid basis, including, but not limited to, a nonprofit service corporation, a health maintenance organization, the Rhode Island Medicaid program, including its contracted managed care entities, or an entity offering a policy of accident and sickness insurance.

(6) “Person” shall mean a natural person, corporation, mutual company, unincorporated association, partnership, joint venture, limited liability company, trust, estate, foundation, nonprofit corporation, unincorporated organization, or government or governmental subdivision or agency.

(7) “Pharmacy benefit manager” shall mean any person or business, who administers the prescription drug or device program of one or more health plans on behalf of a third party, in accordance with a pharmacy benefit program. This term includes any agent or representative of a pharmacy benefit manager hired or contracted by the pharmacy benefit manager to assist in the administering of the drug program and any wholly or partially owned or controlled subsidiary of a pharmacy benefit manager.

SECTION 2. Chapter 27-20.8 of the General Laws entitled "Prescription Drug Benefits" is hereby amended by adding thereto the following section: 27-20.8-5. Cost sharing calculation.

(a) When calculating an enrollee’s overall contribution to any out-of-pocket maximum or any cost sharing requirement under a health plan, an insurer or pharmacy benefit manager shall include any amounts paid by the enrollee or paid on behalf of the enrollee by another person that is either:

(1) Without a generic equivalent; or

(2) With a generic equivalent, where the enrollee has obtained access to the prescription drug through any of the following:

(i) Prior authorization;

(ii) A step therapy protocol; or

(iii) The healthcare plan or carrier’s exceptions and appeals process.

(b) If under federal law, application of subsection (a) of this section would result in Health Savings Account ineligibility under § 223 of the federal Internal Revenue Code ("IRC"), this requirement shall apply only for Health Savings Account qualified High Deductible Health Plans with respect to the deductible of such a plan after the enrollee has satisfied the minimum deductible under § 223, except for items or services that are preventive care pursuant to § 223(c)(2)(C) of the federal Internal Revenue Code, in which case the requirements of subsection (a) of this section shall apply regardless of satisfaction of the minimum deductible under § 223 of the IRC.

(c) This section shall apply with respect to health plans that are entered into, amended, extended, or renewed on or after January 1, 2027.

SECTION 3. This act shall take effect upon passage.